High Prevalence of Triple-Negative Breast Cancer in Southern Shaanxi Province, China

Figures & data

Table 1 Demographic Characteristics of Breast Cancer Patients Included in Study

Variables	Number (%)
Age	50.49±10.55
Tumor location
Left	173 (52.74)
Right	155 (47.26)
Clinical stage
1	27 (8.23)
2	196 (59.76)
3	93 (28.35)
4	12 (3.66)
Molecular subtype
Luminal A	87 (26.52)
Luminal B	105 (32.01)
Triple negative	97 (29.57)
HER2 type	39 (11.89)
T stage
T1	132 (40.24)
T2	108 (32.93)
T3	51 (15.55)
T4	37 (11.28)
N stage
N0	148 (40.55)
N1	119 (32.60)
N2	76 (20.82)
N3	22 (6.02)

Table 2 Breast Cancer Subtypes in Our Patients

Features	Total	Luminal A Number (%)	Luminal B Number (%)	Triple Negative Number (%)	HER2 Type Number (%)	P value
Age						0.012
<50	159	25 (15.72)	37 (23.27)	89 (55.97)	8 (5.03)
≥50	169	22 (13.02)	18 (10.65)	118 (69.82)	11 (6.51)
Ki-67 expression						<2.1×10^−15
<20%	95	58 (61.05)	11 (11.58)	20 (21.05)	6 (7.22)
≥20%	233	0 (0)	45 (19.31)	179 (76.82)	9 (3.86)
Clinical stage						0.046
I	27	9 (33.33)	3 (11.11)	13 (48.15)	2 (7.41)
II	196	25 (12.76)	28 (14.29)	132 (67.35)	11 (5.61)
III	93	10 (10.75)	19 (20.43)	59 (63.44)	5 (5.37)
IV	12	3 (25.00)	5 (41.67)	3 (25.00)	1 (8.33)
T stage						0.008
1	45	12 (26.67)	3 (6.67)	27 (60.00)	3 (6.67)
2	229	31 (13.54)	36 (15.72)	151 (65.94)	11 (4.80)
3	44	2 (9.52)	12 (27.27)	27 (61.36)	3 (6.81)
4	10	2 (20.00)	4 (40.00)	2 (20.00)	2 (20.00)
N stage						0.084
0	132	24 (18.18)	17 (12.88)	83 (62.88)	8 (6.06)
1	108	11 (10.19)	15 (13.89)	76 (70.37)	6 (5.56)
2	51	10 (19.60)	14 (27.44)	25 (49.02)	2 (3.91)
3	37	4 (10.81)	8 (21.62)	16 (43.24)	9 (24.33)

Abbreviation: HER2, human epidermal growth factor receptor-2.

Table 3 Ki-67 Expression Between Groups

Biomarkers	Number of Cases	Ki-67 Level (%) (Mean±SD)	P-value
ER+ and/or PR+	97	19.48±17.48	<2×10^−16
ER-/PR-	206	57.38±19.42
HER2+	24	36.71±21.59	0.098
HER2-	280	45.83±26.15

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.

Table 4 Correlation Between HER2 and ER/PR Status

Biomarkers	Number of Cases	ER-Number (%)	PR-Number (%)	P-value
HER2+	18
HER2-	310	205 (66.2%)	222 (71.9%)	1.80×10^−4

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.

Table 5 The Treatment Methods and Plan for These Patients

Treatment Methods	Patients (%)	Treatment Plan
Surgical resection
Only tumor resection	2.13
Radical mastectomy	94.10
Breast-conserving therapy	3.76
Chemotherapy	74.72	Epirubicin 50–70 mg/m^2 combined with cyclophosphamide 400–600 mg/m^2 for 3–4 weeks, followed by paclitaxel 135–175 mg/m^2
Radiotherapy	34.95	50–60Gy/25-30f
Endocrine Therapy	29.48	The patients were given tamoxifen or letrozole orally after chemoradiotherapy for 2–5 years when the positive expression of ER was > 5%